Modulation of Estrogen Receptor Alpha Activity and Expression During Breast Cancer Progression

Vitamins and Hormones

Volumn 93, Issue , 2013, Pages 135-160

  Kerdivel, Gwenneg ^a   Flouriot, Gilles ^a   Pakdel, Farzad ^a  

^a UNIVERSITÉ DE RENNES 1   (France)

Author keywords

Breast cancer; Cross talk; Endocrine resistance; Epigenetic; Estrogen; Estrogen receptor; Growth factor signaling; Hormonal therapy; Hormone dependence; Proliferation

Indexed keywords

EID: 84880309719     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-416673-8.00004-6     Document Type: Chapter

References (126)

1. Adams B.D., Cowee D.M., White B.A. The role of miR-206 in the epidermal growth factor (EGF) induced repression of estrogen receptor-alpha (ERalpha) signaling and a luminal phenotype in MCF-7 breast cancer cells. Molecular Endocrinology 2009, 23:1215-1230.
2. Adams B.D., Furneaux H., White B.A. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Molecular Endocrinology 2007, 21:1132-1147.
3. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:3983-3988.
4. Allred D.C., Brown P., Medina D. The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Research 2004, 6:240-245.
5. Anzick S.L., Kononen J., Walker R.L., Azorsa D.O., Tanner M.M., Guan X.Y., et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997, 277:965-968.
6. Bandyopadhyay A., Wang L., Chin S.H., Sun L.-Z. Inhibition of skeletal metastasis by ectopic ERalpha expression in ERalpha-negative human breast cancer cell lines. Neoplasia 2007, 9:113-118.
7. Bayliss J., Hilger A., Vishnu P., Diehl K., El-Ashry D. Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response. Clinical Cancer Research 2007, 13:7029-7036.
8. Bergqvist J., Elmberger G., Ohd J., Linderholm B., Bjohle J., Hellborg H., et al. Activated ERK1/2 and phosphorylated oestrogen receptor alpha are associated with improved breast cancer survival in women treated with tamoxifen. European Journal of Cancer 2006, 42:1104-1112.
9. Bos R., Zhong H., Hanrahan C.F., Mommers E.C., Semenza G.L., Pinedo H.M., et al. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. Journal of the National Cancer Institute 2001, 93:309-314.
10. Boudot A., Kerdivel G., Habauzit D., Eeckhoute J., Le Dily F., Flouriot G., et al. Differential estrogen-regulation of CXCL12 chemokine receptors, CXCR4 and CXCR7, contributes to the growth effect of estrogens in breast cancer cells. PLoS One 2011, 6:e20898.
11. Boudot A., Le Dily F., Pakdel F. Involvement of COUP-TFs in cancer progression. Cancers 2011, 3:700-715.
12. Burkhardt L., Grob T.J., Hermann I., Burandt E., Choschzick M., Jänicke F., et al. Gene amplification in ductal carcinoma in situ of the breast. Breast Cancer Research and Treatment 2010, 123:757-765.
13. Carroll J.S., Liu X.S., Brodsky A.S., Li W., Meyer C.A., Szary A.J., et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 2005, 122:33-43.
14. Castles C.G., Oesterreich S., Hansen R., Fuqua S.A. Auto-regulation of the estrogen receptor promoter. The Journal of Steroid Biochemistry and Molecular Biology 1997, 62:155-163.
15. Chan C.M., Lykkesfeldt A.E., Parker M.G., Dowsett M. Expression of nuclear receptor interacting proteins TIF-1, SUG-1, receptor interacting protein 140, and corepressor SMRT in tamoxifen-resistant breast cancer. Clinical Cancer Research 1999, 5:3460-3467.
16. Chen Z., Ko A., Yang J., Jordan V.C. Methylation of CpG island is not a ubiquitous mechanism for the loss of oestrogen receptor in breast cancer cells. British Journal of Cancer 1998, 77:181-185.
17. Cho J., Kim D., Lee S., Lee Y. Cobalt chloride-induced estrogen receptor Α down-regulation involves hypoxia-inducible factor-1α in MCF-7 human breast cancer cells. Molecular Endocrinology 2005, 19:1191-1199.
18. Conway K., Parrish E., Edmiston S.N., Tolbert D., Tse C.-K., Geradts J., et al. The estrogen receptor-alpha A908G (K303R) mutation occurs at a low frequency in invasive breast tumors: Results from a population-based study. Breast Cancer Research 2005, 7:R871-R880.
19. Cooper C., Liu G.-Y., Niu Y.-L., Santos S., Murphy L.C., Watson P.H. Intermittent hypoxia induces proteasome-dependent down-regulation of estrogen receptor alpha in human breast carcinoma. Clinical Cancer Research 2004, 10:8720-8727.
20. Couse J.F., Korach K.S. Reproductive phenotypes in the estrogen receptor-alpha knockout mouse. Annales d'Endocrinologie 1999, 60:143-148.
21. Daschner P.J., Ciolino H.P., Plouzek C.A., Yeh G.C. Increased AP-1 activity in drug resistant human breast cancer MCF-7 cells. Breast Cancer Research and Treatment 1999, 53:229-240.
22. Denger S., Reid G., Kos M., Flouriot G., Parsch D., Brand H., et al. ERalpha gene expression in human primary osteoblasts: Evidence for the expression of two receptor proteins. Molecular Endocrinology 2001, 15:2064-2077.
23. Dhasarathy A., Kajita M., Wade P.A. The transcription factor snail mediates epithelial to mesenchymal transitions by repression of estrogen receptor-alpha. Molecular Endocrinology 2007, 21:2907-2918.
24. Di Leva G., Gasparini P., Piovan C., Ngankeu A., Garofalo M., Taccioli C., et al. MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. Journal of the National Cancer Institute 2010, 102:706-721.
25. Dumont J.A., Bitonti A.J., Wallace C.D., Baumann R.J., Cashman E.A., Cross-Doersen D.E. Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity. Cell Growth & Differentiation 1996, 7:351-359.
26. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials, 14. Lancet 2005, 365:1687-1717.
27. Falette N.S., Fuqua S.A., Chamness G.C., Cheah M.S., Greene G.L., McGuire W.L. Estrogen receptor gene methylation in human breast tumors. Cancer Research 1990, 50:3974-3978.
28. Ferguson A.T., Lapidus R.G., Baylin S.B., Davidson N.E. Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Research 1995, 55:2279-2283.
29. Fillmore C.M., Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Research 2008, 10:R25.
30. Flouriot G., Brand H., Denger S., Metivier R., Kos M., Reid G., et al. Identification of a new isoform of the human estrogen receptor-alpha (hER-alpha) that is encoded by distinct transcripts and that is able to repress hER-alpha activation function 1. The EMBO Journal 2000, 19:4688-4700.
31. Fuqua S.A., Wiltschke C., Zhang Q.X., Borg A., Castles C.G., Friedrichs W.E., et al. A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Research 2000, 60:4026-4029.
32. Gee J.M., Robertson J.F., Gutteridge E., Ellis I.O., Pinder S.E., Rubini M., et al. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocrine-Related Cancer 2005, 12(Suppl. 1):S99-S111.
33. Girault I., Lerebours F., Amarir S., Tozlu S., Tubiana-Hulin M., Lidereau R., et al. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: Evidence that NCOR1 expression is predictive of the response to tamoxifen. Clinical Cancer Research 2003, 9:1259-1266.
34. Gutierrez M.C., Detre S., Johnston S., Mohsin S.K., Shou J., Allred D.C., et al. Molecular changes in tamoxifen-resistant breast cancer: Relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. Journal of Clinical Oncology 2005, 23:2469-2476.
35. Herynk M.H., Fuqua S.A.W. Estrogen receptor mutations in human disease. Endocrine Reviews 2004, 25:869-898.
36. Herynk M.H., Parra I., Cui Y., Beyer A., Wu M.-F., Hilsenbeck S.G., et al. Association between the estrogen receptor alpha A908G mutation and outcomes in invasive breast cancer. Clinical Cancer Research 2007, 13:3235-3243.
37. Holloway J.N., Murthy S., El-Ashry D. A cytoplasmic substrate of mitogen-activated protein kinase is responsible for estrogen receptor-alpha down-regulation in breast cancer cells: The role of nuclear factor-kappaB. Molecular Endocrinology 2004, 18:1396-1410.
38. Holst F., Stahl P., Hellwinkel O., Dancau A.-M., Krohn A., Wuth L., et al. Reply to "ESR1 gene amplification in breast cancer: A common phenomenon?". Nature Genetics 2008, 40:810-812.
39. Holst F., Stahl P.R., Ruiz C., Hellwinkel O., Jehan Z., Wendland M., et al. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nature Genetics 2007, 39:655-660.
40. Huet G., Mérot Y., Le Dily F., Kern L., Ferrière F., Saligaut C., et al. Loss of E-cadherin-mediated cell contacts reduces estrogen receptor alpha (ER alpha) transcriptional efficiency by affecting the respective contribution exerted by AF1 and AF2 transactivation functions. Biochemical and Biophysical Research Communications 2008, 365:304-309.
41. Huet G., Mérot Y., Percevault F., Tiffoche C., Arnal J.-F., Boujrad N., et al. Repression of the estrogen receptor-alpha transcriptional activity by the Rho/megakaryoblastic leukemia 1 signaling pathway. The Journal of Biological Chemistry 2009, 284:33729-33739.
42. Hurtado A., Holmes K.A., Ross-Innes C.S., Schmidt D., Carroll J.S. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nature Genetics 2011, 43:27-33.
43. Iorio M.V., Ferracin M., Liu C.-G., Veronese A., Spizzo R., Sabbioni S., et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Research 2005, 65:7065-7070.
44. Iwase H., Greenman J.M., Barnes D.M., Bobrow L., Hodgson S., Mathew C.G. Loss of heterozygosity of the oestrogen receptor gene in breast cancer. British Journal of Cancer 1995, 71:448-450.
45. Iwase H., Omoto Y., Iwata H., Toyama T., Hara Y., Ando Y., et al. DNA methylation analysis at distal and proximal promoter regions of the oestrogen receptor gene in breast cancers. British Journal of Cancer 1999, 80:1982-1986.
46. Jiang J., Sarwar N., Peston D., Kulinskaya E., Shousha S., Coombes R.C., et al. Phosphorylation of estrogen receptor-alpha at Ser167 is indicative of longer disease-free and overall survival in breast cancer patients. Clinical Cancer Research 2007, 13:5769-5776.
47. Johnston S.R.D., Saccani-Jotti G., Smith I.E., Salter J., Newby J., Coppen M., et al. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Research 1995, 55:3331-3338.
48. Karamouzis M.V., Konstantinopoulos P.A., Badra F.A., Papavassiliou A.G. SUMO and estrogen receptors in breast cancer. Breast Cancer Research and Treatment 2008, 107:195-210.
49. Karnik P.S., Kulkarni S., Liu X.P., Budd G.T., Bukowski R.M. Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Research 1994, 54:349-353.
50. Kenealy M.-R., Flouriot G., Sonntag-Buck V., Dandekar T., Brand H., Gannon F. The 3'-untranslated region of the human estrogen receptor Α gene mediates rapid messenger ribonucleic acid turnover. Endocrinology 2000, 141:2805-2813.
51. Kerdivel G., Boudot A., Pakdel F. Estrogen represses CXCR7 gene expression by inhibiting the recruitment of NFκB transcription factor at the CXCR7 promoter in breast cancer cells. Biochemical and Biophysical Research Communications 2013, 431:729-733.
52. Klinge C.M., Riggs K.A., Wickramasinghe N.S., Emberts C.G., McConda D.B., Barry P.N., et al. Estrogen receptor alpha 46 is reduced in tamoxifen resistant breast cancer cells and re-expression inhibits cell proliferation and estrogen receptor alpha 66-regulated target gene transcription. Molecular and Cellular Endocrinology 2010, 323:268-276.
53. Koda M., Kanczuga-Koda L., Sulkowska M., Surmacz E., Sulkowski S. Relationships between hypoxia markers and the leptin system, estrogen receptors in human primary and metastatic breast cancer: Effects of preoperative chemotherapy. BMC Cancer 2010, 10:320.
54. Kok M., Zwart W., Holm C., Fles R., Hauptmann M., Van't Veer L.J., et al. PKA-induced phosphorylation of ERα at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer. Breast Cancer Research and Treatment 2011, 125:1-12.
55. Kondo N., Toyama T., Sugiura H., Fujii Y., Yamashita H. miR-206 expression is down-regulated in estrogen receptor alpha-positive human breast cancer. Cancer Research 2008, 68:5004-5008.
56. Konecny G., Pauletti G., Pegram M., Untch M., Dandekar S., Aguilar Z., et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. Journal of the National Cancer Institute 2003, 95:142-153.
57. Korkaya H., Paulson A., Iovino F., Wicha M.S. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 2008, 27:6120-6130.
58. Kurebayashi J., Otsuki T., Kunisue H., Tanaka K., Yamamoto S., Sonoo H. Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer. Clinical Cancer Research 2000, 6:512-518.
59. Kurebayashi J., Otsuki T., Moriya T., Sonoo H. Hypoxia reduces hormone responsiveness of human breast cancer cells. Japanese Journal of Cancer Research 2001, 92:1093-1101.
60. Kurokawa H., Arteaga C.L. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clinical Cancer Research 2003, 9:511S-515S.
61. Lal P., Tan L.K., Chen B. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. American Journal of Clinical Pathology 2005, 123:541-546.
62. Lapidus R.G., Ferguson A.T., Ottaviano Y.L., Parl F.F., Smith H.S., Weitzman S.A., et al. Methylation of estrogen and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clinical Cancer Research 1996, 2:805-810.
63. Lavinsky R.M., Jepsen K., Heinzel T., Torchia J., Mullen T.-M., Schiff R., et al. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. PNAS 1998, 95:2920-2925.
64. Le Dily F., Métivier R., Guéguen M.-M., Le Péron C., Flouriot G., Tas P., et al. COUP-TFI modulates estrogen signaling and influences proliferation, survival and migration of breast cancer cells. Breast Cancer Research and Treatment 2008, 110:69-83.
65. Le Romancer M., Poulard C., Cohen P., Sentis S., Renoir J.-M., Corbo L. Cracking the estrogen receptor's posttranslational code in breast tumors. Endocrine Reviews 2011, 32:597-622.
66. Le Romancer M., Treilleux I., Bouchekioua-Bouzaghou K., Sentis S., Corbo L. Methylation, a key step for nongenomic estrogen signaling in breast tumors. Steroids 2010, 75:560-564.
67. Le Romancer M., Treilleux I., Leconte N., Robin-Lespinasse Y., Sentis S., Bouchekioua-Bouzaghou K., et al. Regulation of estrogen rapid signaling through arginine methylation by PRMT1. Molecular Cell 2008, 31:212-221.
68. Leivonen S.-K., Mäkelä R., Ostling P., Kohonen P., Haapa-Paananen S., Kleivi K., et al. Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines. Oncogene 2009, 28:3926-3936.
69. Levin E., Pietras R. Estrogen receptors outside the nucleus in breast cancer. Breast Cancer Research and Treatment 2008, 108:351-361.
70. Louie M.C., Zou J.X., Rabinovich A., Chen H.-W. ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance. Molecular and Cellular Biology 2004, 24:5157-5171.
71. Magnani L., Ballantyne E.B., Zhang X., Lupien M. PBX1 genomic pioneer function drives ERα signaling underlying progression in breast cancer. PLoS Genetics 2011, 7:e1002368.
72. Massarweh S., Osborne C.K., Creighton C.J., Qin L., Tsimelzon A., Huang S., et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Research 2008, 68:826-833.
73. Massarweh S., Schiff R. Resistance to endocrine therapy in breast cancer: Exploiting estrogen receptor/growth factor signaling crosstalk. Endocrine-Related Cancer 2006, 13(Suppl. 1):S15-S24.
74. Métivier R., Gay F.A., Hübner M.R., Flouriot G., Salbert G., Gannon F., et al. Formation of an hER alpha-COUP-TFI complex enhances hER alpha AF-1 through Ser118 phosphorylation by MAPK. The EMBO Journal 2002, 21:3443-3453.
75. Mironchik Y., Winnard P.T., Vesuna F., Kato Y., Wildes F., Pathak A.P., et al. Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer. Cancer Research 2005, 65:10801-10809.
76. Moelans C.B., Monsuur H.N., de Pinth J.H., Radersma R.D., de Weger R.A., van Diest P.J. ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: A multiplex ligation-dependent probe amplification study. Analytical Cellular Pathology (Amsterdam) 2010, 33:13-18.
77. Munzone E., Curigliano G., Rocca A., Bonizzi G., Renne G., Goldhirsch A., et al. Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. Breast Cancer Research 2006, 8:R4.
78. Murphy L.C., Niu Y., Snell L., Watson P. Phospho-serine-118 estrogen receptor-alpha expression is associated with better disease outcome in women treated with tamoxifen. Clinical Cancer Research 2004, 10:5902-5906.
79. Murphy L.C., Seekallu S.V., Watson P.H. Clinical significance of estrogen receptor phosphorylation. Endocrine-Related Cancer 2011, 18:R1-R14.
80. Murphy L.C., Simon S.L., Parkes A., Leygue E., Dotzlaw H., Snell L., et al. Altered expression of estrogen receptor coregulators during human breast tumorigenesis. Cancer Research 2000, 60:6266-6271.
81. Murphy L.C., Wang M., Coutt A., Dotzlaw H. Novel mutations in the estrogen receptor messenger RNA in human breast cancers. The Journal of Clinical Endocrinology and Metabolism 1996, 81:1420-1427.
82. O'Brien C.S., Farnie G., Howell S.J., Clarke R.B. Breast cancer stem cells and their role in resistance to endocrine therapy. Hormones & Cancer 2011, 2:91-103.
83. Oh A.S., Lorant L.A., Holloway J.N., Miller D.L., Kern F.G., El-Ashry D. Hyperactivation of MAPK induces loss of ERα expression in breast cancer cells. Molecular Endocrinology 2001, 15:1344-1359.
84. Ottaviano Y.L., Issa J.P., Parl F.F., Smith H.S., Baylin S.B., Davidson N.E. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Research 1994, 54:2552-2555.
85. Penot G., Le Péron C., Mérot Y., Grimaud-Fanouillère E., Ferrière F., Boujrad N., et al. The human estrogen receptor-alpha isoform hERalpha46 antagonizes the proliferative influence of hERalpha66 in MCF7 breast cancer cells. Endocrinology 2005, 146:5474-5484.
86. Piva R., Rimondi A.P., Hanau S., Maestri I., Alvisi A., Kumar V.L., et al. Different methylation of oestrogen receptor DNA in human breast carcinomas with and without oestrogen receptor. British Journal of Cancer 1990, 61:270-275.
87. Platet N., Cathiard A.M., Gleizes M., Garcia M. Estrogens and their receptors in breast cancer progression: A dual role in cancer proliferation and invasion. Critical Reviews in Oncology/Hematology 2004, 51:55-67.
88. Prabhu J.S., Wahi K., Korlimarla A., Correa M., Manjunath S., Raman N., et al. The epigenetic silencing of the estrogen receptor (ER) by hypermethylation of the ESR1 promoter is seen predominantly in triple-negative breast cancers in Indian women. Tumour Biology 2012, 33:315-323.
89. Rexer B.N., Arteaga C.L. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: Mechanisms and clinical implications. Critical Reviews in Oncogenesis 2012, 17:1-16.
90. Roodi N., Bailey L.R., Kao W.-Y., Verrier C.S., Yee C.J., Dupont W.D., et al. Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. Journal of the National Cancer Institute 1995, 87:446-451.
91. Ross-Innes C.S., Stark R., Teschendorff A.E., Holmes K.A., Ali H.R., Dunning M.J., et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 2012, 481:389-393.
92. Ryu K., Park C., Lee Y. Hypoxia-inducible factor 1 alpha represses the transcription of the estrogen receptor alpha gene in human breast cancer cells. Biochemical and Biophysical Research Communications 2011, 407:831-836.
93. Sentis S., Le Romancer M., Bianchin C., Rostan M.-C., Corbo L. Sumoylation of the estrogen receptor alpha hinge region regulates its transcriptional activity. Molecular Endocrinology 2005, 19:2671-2684.
94. Shi L., Dong B., Li Z., Lu Y., Ouyang T., Li J., et al. Expression of ER-α36, a novel variant of estrogen receptor α, and resistance to tamoxifen treatment in breast cancer. Journal of Clinical Oncology 2009, 27:3423-3429.
95. Shipitsin M., Campbell L.L., Argani P., Weremowicz S., Bloushtain-Qimron N., Yao J., et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007, 11:259-273.
96. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA: A Cancer Journal for Clinicians 2012, 62:10-29.
97. Skliris G.P., Nugent Z.J., Rowan B.G., Penner C.R., Watson P.H., Murphy L.C. A phosphorylation code for oestrogen receptor-Α predicts clinical outcome to endocrine therapy in breast cancer. Endocrine-Related Cancer 2010, 17:589-597.
98. Skliris G.P., Nugent Z., Watson P.H., Murphy L.C. Estrogen receptor alpha phosphorylated at tyrosine 537 is associated with poor clinical outcome in breast cancer patients treated with tamoxifen. Hormones & Cancer 2010, 1:215-221.
99. Smith L.M., Wise S.C., Hendricks D.T., Sabichi A.L., Bos T., Reddy P., et al. cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene 1999, 18:6063-6070.
100. Spears M., Oesterreich S., Migliaccio I., Guiterrez C., Hilsenbeck S., Quintayo M.A., et al. The p160 ER co-regulators predict outcome in ER negative breast cancer. Breast Cancer Research and Treatment 2012, 131:463-472.
101. Stender J.D., Kim K., Charn T.H., Komm B., Chang K.C.N., Kraus W.L., et al. Genome-wide analysis of estrogen receptor α DNA binding and tethering mechanisms identifies Runx1 as a novel tethering factor in receptor-mediated transcriptional activation. Molecular and Cellular Biology 2010, 30:3943-3955.
102. Stoner M., Saville B., Wormke M., Dean D., Burghardt R., Safe S. Hypoxia induces proteasome-dependent degradation of estrogen receptor alpha in ZR-75 breast cancer cells. Molecular Endocrinology 2002, 16:2231-2242.
103. Stossi F., Madak-Erdoǧan Z., Katzenellenbogen B.S. Macrophage-elicited loss of estrogen receptor-α in breast cancer cells via involvement of MAPK and c-Jun at the ESR1 genomic locus. Oncogene 2012, 31:1825-1834.
104. Tang Z., Treilleux I., Brown M. A transcriptional enhancer required for the differential expression of the human estrogen receptor in breast cancers. Molecular and Cellular Biology 1997, 17:1274-1280.
105. Teyssier C., Le Romancer M., Sentis S., Jalaguier S., Corbo L., Cavaillès V. Protein arginine methylation in estrogen signaling and estrogen-related cancers. Trends in Endocrinology and Metabolism 2010, 21:181-189.
106. Vadlamudi R.K., Kumar R. Functional and biological properties of the nuclear receptor coregulator PELP1/MNAR. Nuclear Receptor Signaling 2007, 5:e004.
107. Vallabhaneni S., Nair B.C., Cortez V., Challa R., Chakravarty D., Tekmal R.R., et al. Significance of ER-Src axis in hormonal therapy resistance. Breast Cancer Research and Treatment 2011, 130:377-385.
108. Vesuna F., Lisok A., Kimble B., Domek J., Kato Y., van der Groep P., et al. Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-α. Oncogene 2011, 31:3223-3234.
109. Wang L., Banerjee S. Differential PIAS3 expression in human malignancy. Oncology Reports 2004, 11:1319-1324.
110. Wang C., Fu M., Angeletti R.H., Siconolfi-Baez L., Reutens A.T., Albanese C., et al. Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity. The Journal of Biological Chemistry 2001, 276:18375-18383.
111. Wang Z., Zhang X., Shen P., Loggie B.W., Chang Y., Deuel T.F. Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66. Biochemical and Biophysical Research Communications 2005, 336:1023-1027.
112. Wang Z., Zhang X., Shen P., Loggie B.W., Chang Y., Deuel T.F. A variant of estrogen receptor-{alpha}, hER-{alpha}36: Transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:9063-9068.
113. Xia W., Bacus S., Hegde P., Husain I., Strum J., Liu L., et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:7795-7800.
114. Xiong J. Emerging roles of microRNA-22 in human disease and normal physiology. Current Molecular Medicine 2012, 12:247-258.
115. Xiong J., Yu D., Wei N., Fu H., Cai T., Huang Y., et al. An estrogen receptor alpha suppressor, microRNA-22, is downregulated in estrogen receptor alpha-positive human breast cancer cell lines and clinical samples. The FEBS Journal 2010, 277:1684-1694.
116. Yamamoto Y., Ibusuki M., Okumura Y., Kawasoe T., Kai K., Iyama K., et al. Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer. Breast Cancer Research and Treatment 2008, 110:465-475.
117. Yan X., Fu C., Chen L., Qin J., Zeng Q., Yuan H., et al. Mesenchymal stem cells from primary breast cancer tissue promote cancer proliferation and enhance mammosphere formation partially via EGF/EGFR/Akt pathway. Breast Cancer Research and Treatment 2012, 132:153-164.
118. Yan L., Yang X., Davidson N.E. Role of DNA methylation and histone acetylation in steroid receptor expression in breast cancer. Journal of Mammary Gland Biology and Neoplasia 2001, 6:183-192.
119. Yoshida T., Eguchi H., Nakachi K., Tanimoto K., Higashi Y., Suemasu K., et al. Distinct mechanisms of loss of estrogen receptor alpha gene expression in human breast cancer: Methylation of the gene and alteration of trans-acting factors. Carcinogenesis 2000, 21:2193-2201.
120. Yoshimoto N., Toyama T., Takahashi S., Sugiura H., Endo Y., Iwasa M., et al. Distinct expressions of microRNAs that directly target estrogen receptor α in human breast cancer. Breast Cancer Research and Treatment 2011, 130:331-339.
121. Zhang Q.X., Hilsenbeck S.G., Fuqua S.A., Borg A. Multiple splicing variants of the estrogen receptor are present in individual human breast tumors. The Journal of Steroid Biochemistry and Molecular Biology 1996, 59:251-260.
122. Zhao J.-J., Lin J., Yang H., Kong W., He L., Ma X., et al. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. The Journal of Biological Chemistry 2008, 283:31079-31086.
123. Zhou Y., Eppenberger-Castori S., Eppenberger U., Benz C.C. The NFkappaB pathway and endocrine-resistant breast cancer. Endocrine-Related Cancer 2005, 12(Suppl. 1):S37-S46.
124. Zhou Y., Yau C., Gray J.W., Chew K., Dairkee S.H., Moore D.H., et al. Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer 2007, 7:59.
125. Zoubir M., Mathieu M.C., Mazouni C., Liedtke C., Corley L., Geha S., et al. Modulation of ER phosphorylation on serine 118 by endocrine therapy: A new surrogate marker for efficacy. Annals of Oncology 2008, 19:1402-1406.
126. Zwart W., Griekspoor A., Berno V., Lakeman K., Jalink K., Mancini M., et al. PKA-induced resistance to tamoxifen is associated with an altered orientation of ERalpha towards co-activator SRC-1. The EMBO Journal 2007, 26:3534-3544.